S&P 500   3,658.56 (+2.03%)
DOW   29,360.56 (+2.21%)
QQQ   270.49 (+1.21%)
AAPL   141.00 (+2.03%)
MSFT   237.29 (+1.88%)
META   138.65 (+2.19%)
GOOGL   97.78 (+2.23%)
AMZN   114.48 (+1.31%)
TSLA   247.37 (-6.74%)
NVDA   124.78 (+2.79%)
NIO   15.77 (+0.00%)
BABA   80.09 (+0.13%)
AMD   65.77 (+3.80%)
T   15.95 (+3.98%)
MU   52.63 (+5.05%)
CGC   2.83 (+3.66%)
F   11.50 (+2.68%)
GE   63.72 (+2.92%)
DIS   95.94 (+1.71%)
AMC   6.81 (-2.30%)
PYPL   86.63 (+0.65%)
PFE   43.80 (+0.09%)
NFLX   235.16 (-0.12%)
S&P 500   3,658.56 (+2.03%)
DOW   29,360.56 (+2.21%)
QQQ   270.49 (+1.21%)
AAPL   141.00 (+2.03%)
MSFT   237.29 (+1.88%)
META   138.65 (+2.19%)
GOOGL   97.78 (+2.23%)
AMZN   114.48 (+1.31%)
TSLA   247.37 (-6.74%)
NVDA   124.78 (+2.79%)
NIO   15.77 (+0.00%)
BABA   80.09 (+0.13%)
AMD   65.77 (+3.80%)
T   15.95 (+3.98%)
MU   52.63 (+5.05%)
CGC   2.83 (+3.66%)
F   11.50 (+2.68%)
GE   63.72 (+2.92%)
DIS   95.94 (+1.71%)
AMC   6.81 (-2.30%)
PYPL   86.63 (+0.65%)
PFE   43.80 (+0.09%)
NFLX   235.16 (-0.12%)
S&P 500   3,658.56 (+2.03%)
DOW   29,360.56 (+2.21%)
QQQ   270.49 (+1.21%)
AAPL   141.00 (+2.03%)
MSFT   237.29 (+1.88%)
META   138.65 (+2.19%)
GOOGL   97.78 (+2.23%)
AMZN   114.48 (+1.31%)
TSLA   247.37 (-6.74%)
NVDA   124.78 (+2.79%)
NIO   15.77 (+0.00%)
BABA   80.09 (+0.13%)
AMD   65.77 (+3.80%)
T   15.95 (+3.98%)
MU   52.63 (+5.05%)
CGC   2.83 (+3.66%)
F   11.50 (+2.68%)
GE   63.72 (+2.92%)
DIS   95.94 (+1.71%)
AMC   6.81 (-2.30%)
PYPL   86.63 (+0.65%)
PFE   43.80 (+0.09%)
NFLX   235.16 (-0.12%)
S&P 500   3,658.56 (+2.03%)
DOW   29,360.56 (+2.21%)
QQQ   270.49 (+1.21%)
AAPL   141.00 (+2.03%)
MSFT   237.29 (+1.88%)
META   138.65 (+2.19%)
GOOGL   97.78 (+2.23%)
AMZN   114.48 (+1.31%)
TSLA   247.37 (-6.74%)
NVDA   124.78 (+2.79%)
NIO   15.77 (+0.00%)
BABA   80.09 (+0.13%)
AMD   65.77 (+3.80%)
T   15.95 (+3.98%)
MU   52.63 (+5.05%)
CGC   2.83 (+3.66%)
F   11.50 (+2.68%)
GE   63.72 (+2.92%)
DIS   95.94 (+1.71%)
AMC   6.81 (-2.30%)
PYPL   86.63 (+0.65%)
PFE   43.80 (+0.09%)
NFLX   235.16 (-0.12%)
NASDAQ:MEIP

MEI Pharma - MEIP Stock Forecast, Price & News

$0.40
+0.01 (+2.95%)
(As of 10/3/2022 10:36 AM ET)
Add
Compare
Today's Range
$0.40
$0.40
50-Day Range
$0.39
$0.58
52-Week Range
$0.38
$3.55
Volume
1,200 shs
Average Volume
3.41 million shs
Market Capitalization
$53.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

MEI Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
669.2% Upside
$3.00 Price Target
Short Interest
Healthy
3.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.41mentions of MEI Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

312th out of 1,093 stocks

Pharmaceutical Preparations Industry

136th out of 548 stocks

MEIP stock logo

About MEI Pharma (NASDAQ:MEIP) Stock

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Stock News Headlines

MEI Pharma, Inc. (MEIP)
MEI Pharma Announces Changes to Board of Directors
MEI Pharma stock trades higher as FY22 revenue grows 17%
MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
1MEIP : Earnings Outlook For MEI Pharma
GreenWood Investors Second Quarter 2022 Letter
See More Headlines
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Company Calendar

Last Earnings
9/08/2022
Today
10/03/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+653.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-54,450,000.00
Pretax Margin
-133.80%

Debt

Sales & Book Value

Annual Sales
$40.70 million
Book Value
$0.39 per share

Miscellaneous

Free Float
125,705,000
Market Cap
$53.04 million
Optionable
Optionable
Beta
0.91

Key Executives

  • Dr. Daniel P. Gold (Age 68)
    Pres, CEO & Director
    Comp: $1.03M
  • Mr. Brian G. Drazba B.A. (Age 61)
    CPA, CPA, Chief Financial Officer
    Comp: $544.07k
  • Mr. David M. Urso B.A. (Age 58)
    Esq., J.D., COO & Gen. Counsel
    Comp: $680.47k
  • Dr. Robert D. Mass (Age 68)
    Strategic Advisor
    Comp: $201.68k
  • Dr. Richard G. Ghalie (Age 64)
    Chief Medical Officer
    Comp: $550.55k
  • Ms. Virginia Sankey
    VP of Fin.
  • Dr. Eric Deng Ph.D.
    VP of Technical Operations
  • Ms. Tina Clark Beamon Esq.
    J.D., Chief Compliance Officer
  • Mr. Eugene Park
    VP of Marketing
  • Ms. Anne Frese
    Chief People Officer













MEIP Stock - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings
or view top-rated stocks.

What is MEI Pharma's stock price forecast for 2022?

5 brokerages have issued twelve-month price targets for MEI Pharma's shares. Their MEIP share price forecasts range from $1.00 to $5.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 676.0% from the stock's current price.
View analysts price targets for MEIP
or view top-rated stocks among Wall Street analysts.

How have MEIP shares performed in 2022?

MEI Pharma's stock was trading at $2.67 on January 1st, 2022. Since then, MEIP shares have decreased by 85.5% and is now trading at $0.3866.
View the best growth stocks for 2022 here
.

When is MEI Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MEIP earnings forecast
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) posted its quarterly earnings results on Thursday, September, 8th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.06. MEI Pharma had a negative net margin of 80.49% and a negative trailing twelve-month return on equity of 110.92%.

What other stocks do shareholders of MEI Pharma own?
What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $0.39.

How much money does MEI Pharma make?

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $51.52 million and generates $40.70 million in revenue each year. The company earns $-54,450,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.

This page (NASDAQ:MEIP) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.